impact of the pharmacy closed formulary · 2020. 7. 15. · february 2015 3 . summary of key...

35
Impact of the Texas Pharmacy Closed Formulary A Preliminary Report Based on 12-month Injuries with 24-month Services and Legacy Status Texas Department of Insurance Workers’ Compensation Research and Evaluation Group February 2015

Upload: others

Post on 15-Sep-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

Impact of the Texas Pharmacy Closed Formulary

A Preliminary Report Based on 12-month Injuries with 24-month Services

and Legacy Status

Texas Department of Insurance Workers’ Compensation Research and Evaluation Group

February 2015

Page 2: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 2

Data and methods

• Injury months: 12 months (September–August) • Injury years: 2009–2011 • Prescription months: 24 months maturity per claim • Injuries in 2011 are new injuries that occurred after the

implementation of the pharmacy closed formulary – Injury year from September 2011 to August 2012 – Services covering from September 2011 to August 2013

• Not Recommended drugs (N-drugs) list: approximately 150 drugs that require carrier preauthorization

• Key measures: Claim counts Prescription costs Prescription utilization patterns

Generic substitution rates Cost and utilization by drug group Most prescribed drugs

Page 3: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 3

Summary of key findings: New claims

New claims with injuries that occurred on or after September 1, 2011 are subject to the implementation of the Pharmacy Closed Formulary.

• The number of injured employees receiving N-drugs fell by 65 percent.

• N-drug costs fell by 83 percent, and N-drug costs as a percentage of all drug costs decreased by 79 percent (from 17 percent of total to 3 percent of total).

• The number of injured employees receiving other drugs fell by 1 percent.

• The share of N-drug claims among all claims fell from 18 percent to 7 percent.

• The total number of prescriptions for N-drugs fell by 76 percent while it fell by 4 percent for other drugs.

• The average number of N-drug prescriptions per claim fell by 31 percent.

• The generic substitution rate for N-drugs increased from 61 percent in 2010 to 74 percent in 2011.

• The number of N-drug prescriptions fell by 65+ percent across all drug groups.

• The number of prescriptions for the ten most-prescribed N-drugs decreased by 82 percent.

Page 4: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 4

Summary of key findings: Legacy claims

Legacy claims with injuries prior to September 1, 2011 are subject to the Pharmacy Closed Formulary beginning on September 1, 2013.

• Legacy claims accounted for 38 percent of the claims and 57 percent of the total pharmacy cost in September 2014.

• Legacy claims serviced in a month decreased from 35,604 in September 2011 to 12,215 in September 2014 (66 percent decrease), mainly because there are no new claims added.

• The average pharmacy cost per legacy claim dropped by 18 percent in the first month they became subject to the pharmacy closed formulary (September 2013).

• Total cost of N-drugs decreased from $1.42 million in August 2013 to $607,000 in September 2013 (57 percent decrease), and decreased to $290,000 in September 2014.

• For legacy claims, the share of N-drug cost in the total cost dropped from 18.5 percent in August 2013 to 10.4 percent in September 2013 (44 percent decrease). N-drugs accounted for 6 percent of the total cost in September 2014.

Page 5: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 5

New Claims

with Injury Dates on or after September 1, 2011

(Subject to the Pharmacy Closed Formulary Beginning on September 1, 2011)

Page 6: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 6

New Claims: Number of Claims

Page 7: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 7

Number of claims receiving pharmaceuticals, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

Injury year 2010-2011

percentage change 2009 2010 2011

All claims 106,113 108,642 105,847 -3%

N-drugs

Number of claims 20,966 20,013 6,954 -65%

Percent of all claims 20% 18% 7% -64%

Other drugs

Number of claims with at least one Other drug 103,671 106,313 105,312 -1%

Number of claims with Other drugs only (no N-drugs) 85,147 88,629 98,893 12%

Percent of all claims 80% 82% 93% 15%

Page 8: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 8

Number of claims, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

106,113 108,642 105,847

85,147 88,629

98,893

20,966 20,013

6,954

0

20,000

40,000

60,000

80,000

100,000

120,000

2009 2010 2011

All claims

Without N-drugs

With N-drugs

Page 9: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 9

New Claims: Prescription Costs

Page 10: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 10

Cost of N-drugs, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

Injury year 2010-2011 percentage

change 2009 2010 2011

Total cost $46,234,636 $44,504,995 $37,759,827 -15%

Total cost of N-drug prescriptions $9,609,117 $7,345,534 $1,283,864 -83%

N-drug cost as a percentage of total drug costs 21% 17% 3% -79%

Total number of N-drug prescriptions 76,147 63,343 15,284 -76%

Average cost per N-drug prescription $126 $116 $84 -28%

Total number of N-drug claims 20,966 20,013 6,954 -65%

Average N-drug cost per claim $458 $367 $185 -50%

Page 11: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 11

Total and average costs: N-drugs, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

$401

$328

$168

$124 $113 $81

$9,609,117

$7,345,534

$1,283,864

$0

$1,000,000

$2,000,000

$3,000,000

$4,000,000

$5,000,000

$6,000,000

$7,000,000

$8,000,000

$9,000,000

$10,000,000

$0

$100

$200

$300

$400

$500

2009 2010 2011

Cost per claim Cost per prescription Total N-drug cost

Page 12: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 12

Cost of Other drugs, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

Injury year 2010-2011 percentage

change 2009 2010 2011

Total cost $46,234,636 $44,504,995 $37,759,827 -15%

Total cost of Other drug prescriptions $36,625,519 $37,159,460 $36,475,964 -2%

Other drug cost as a percentage of total drug costs 79% 83% 97% 16%

Total number of Other drug prescriptions 632,739 648,672 624,676 -4%

Average cost per Other drug prescription $58 $57 $58 2%

Total number of Other drug claims 103,671 106,313 105,312 -1%

Average Other drug cost per claim $353 $350 $346 -1%

Page 13: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 13

Total and average costs: Other drugs, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

$353 $350 $346

$58 $57 $58

$36,625,519 $37,159,460 $36,475,964

$5,000,000

$10,000,000

$15,000,000

$20,000,000

$25,000,000

$30,000,000

$35,000,000

$0

$50

$100

$150

$200

$250

$300

$350

$400

$450

$500

2009 2010 2011

Cost per claim Cost per prescription Total Other drug cost

Page 14: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 14

New Claims: Prescription Patterns

Page 15: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 15

Share of prescriptions by drug type, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

Injury year 2010-2011

percentage change 2009 2010 2011

Total number of all prescriptions 708,886 712,015 639,960 -10%

N-drugs

Number of prescriptions 76,147 63,343 15,284 -76%

N-drug prescriptions as a percent of all prescriptions 11% 9% 2% -73%

Other drugs

Number of prescriptions 632,739 648,672 624,676 -4%

Other drug prescriptions as a percent of all prescriptions 89% 91% 98% 7%

Page 16: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 16

Number of prescriptions per claim, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

Injury year 2010-2011 percentage

change 2009 2010 2011

N-drugs

Number of prescriptions 76,147 63,343 15,284 -76%

Total N-drug claims 20,966 20,013 6,954 -65%

Number of prescriptions per claim 3.63 3.17 2.20 -31%

Other drugs

Number of prescriptions 632,739 648,672 624,676 -4%

Total Other drug claims 103,671 106,313 105,312 -1%

Number of prescriptions per claim 6.10 6.10 5.93 -3%

Page 17: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 17

New Claims: Generic Substitution Rates

Page 18: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 18

Generic substitution: prescriptions of N-drugs, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

24,482

3,983

38,861

11,301

0

5,000

10,000

15,000

20,000

25,000

30,000

35,000

40,000

45,000

2010 2011

Brand Generic

(39%)

(61%)

(26%)

(74%)

Page 19: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 19

Generic substitution: prescriptions of Other drugs, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

62,707 49,217

572,270 559,035

0

100,000

200,000

300,000

400,000

500,000

600,000

700,000

2010 2011

Brand Generic

(90%)

(10%) (8%)

(92%)

Page 20: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 20

Average number of N-drug prescription days by generic status, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

22.8 20.4 20.5 19.9

0.0

5.0

10.0

15.0

20.0

25.0

2010 2011

Brand Generic

Page 21: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 21

New Claims: Cost and Utilization by Drug Group

Page 22: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 22

Number of prescriptions by drug group, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

N-drug Status Drug group

Number of prescriptions

2010

Number of prescriptions

2011

2010 - 2011 percentage

change

N-drugs

Analgesics - Anti-Inflammatory 15,138 3,455 -77%

Analgesics - Opioid 8,188 2,875 -65%

Central Nervous System Drugs 15,728 4,442 -72%

Musculoskeletal Therapy Agents 13,300 1,703 -87%

Others 10,989 2,809 -74%

Total 63,343 15,284 -76%

Other drugs

Analgesics - Anti-Inflammatory 154,030 153,521 0%

Analgesics - Opioid 231,971 209,989 -9%

Central Nervous System Drugs 45,549 43,583 -4%

Musculoskeletal Therapy Agents 90,891 90,787 0%

Others 126,231 126,796 0%

Total 648,672 624,676 -4%

Page 23: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 23

Total cost by drug group, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

N-drug Status Drug group Total cost

2010 Total cost

2011

2010 - 2011 percentage

change

N-drugs

Analgesics - Anti-Inflammatory $1,723,884 $204,116 -88%

Analgesics - Opioid $1,264,710 $346,970 -73%

Central Nervous System Drugs $1,025,308 $285,451 -72%

Musculoskeletal Therapy Agents $1,064,535 $67,239 -94%

Others $2,267,097 $380,087 -83%

Total $7,345,534 $1,283,864 -83%

Other drugs

Analgesics - Anti-Inflammatory $9,755,521 $9,535,053 -2%

Analgesics - Opioid $7,651,679 $6,489,643 -15%

Central Nervous System Drugs $5,798,464 $5,697,524 -2%

Musculoskeletal Therapy Agents $5,539,819 $5,032,235 -9%

Others $8,413,977 $9,721,508 16%

Total $37,159,460 $36,475,964 -2%

Page 24: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 24

Average cost per claim by drug group, by injury year (Sept.–Aug.)

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

N-drug Status Drug group

Number of claims Cost per claims

2010 2011 2010 2011 2010 - 2011 percentage

change

N-drugs

Analgesics - Anti-Inflammatory 8,444 2,328 $204 $88 -57%

Analgesics - Opioid 2,978 1,267 $425 $274 -36%

Central Nervous System Drugs 3,863 1,441 $265 $198 -25%

Musculoskeletal Therapy Agents 4,816 969 $221 $69 -69%

Others 4,538 1,737 $500 $219 -56%

Other drugs

Analgesics - Anti-Inflammatory 62,672 64,042 $156 $149 -4%

Analgesics - Opioid 59,897 59,012 $128 $110 -14%

Central Nervous System Drugs 8,109 7,922 $715 $719 1%

Musculoskeletal Therapy Agents 34,763 35,761 $159 $141 -12%

Others 46,642 47,271 $180 $206 14%

Page 25: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 25

New Claims: Most Prescribed Drugs

Page 26: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 26

Ten most frequently prescribed drugs, by injury year (Sept.–Aug.)

Note: No N-drug was in the top ten most frequently prescribed drugs in 2010 and 2011. These ten drugs accounted for 60 percent of total prescriptions in 2010, and 65 percent in 2011. Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

2010 rank by number of

prescription Drug name Drug group

Number of prescriptions

2010

Number of prescriptions

2011

1 Hydrocodone/APAP Analgesics - Opioid 158,576 138,468

2 Cyclobenzaprine Musculoskeletal Therapy Agents 56,090 56,917

3 Naproxen Analgesics - Anti-Inflammatory 49,775 50,186

4 Tramadol Analgesics - Opioid 47,521 49,238

5 Ibuprofen Analgesics - Anti-Inflammatory 47,167 49,846

6 Meloxicam Analgesics - Anti-Inflammatory 20,493 21,913

7 Celebrex Analgesics - Anti-Inflammatory 14,308 12,083

8 Gabapentin Central Nervous System Drugs 12,774 13,861

9 Tramadol/APAP Analgesics - Opioid 12,292 12,909

10 Methylpred Others 10,606 11,425

Subtotal 429,602 416,846

Page 27: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 27

Ten most frequently prescribed N-drugs, by injury year (Sept.–Aug.)

Note: These ten drugs accounted for 59 percent of total N-drug prescriptions in 2010, and 44 percent in 2011. Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

2010 rank by number

of Rx Drug name Drug group Number of

Rx in 2010 Number of Rx in 2011

2010-2011 percentage

change

1 Carisoprodol Musculoskeletal Therapy Agents 8,514 1,086 -87%

2 Diclofenac Analgesics - Anti-Inflammatory 4,874 1,944 -60%

3 Zipsor Analgesics - Anti-Inflammatory 3,867 465 -88%

4 Lidoderm Others 3,829 744 -81%

5 Diazepam Central Nervous System Drugs 3,314 771 -77%

6 Naprelan Analgesics - Anti-Inflammatory 2,952 218 -93%

7 Hydrocodone/IBU Analgesics - Opioid 2,541 660 -74%

8 Alprazolam Central Nervous System Drugs 2,503 399 -84%

9 Flector Others 2,454 338 -86%

10 Amrix Musculoskeletal Therapy Agents 2,236 34 -98%

Subtotal 37,084 6,659 -82%

Page 28: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 28

Legacy Claims

with Injury Dates Prior to September 2011

(Subject to the Pharmacy Closed Formulary Beginning on September 1, 2013)

Page 29: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 29

All claims: Number of claims and total cost by service month

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

$0

$2

$4

$6

$8

$10

$12

$14

$16

20,000

25,000

30,000

35,000

40,000

45,000

50,000

55,000

60,000 20

05/0

1 20

05/0

4 20

05/0

7 20

05/1

0 20

06/0

1 20

06/0

4 20

06/0

7 20

06/1

0 20

07/0

1 20

07/0

4 20

07/0

7 20

07/1

0 20

08/0

1 20

08/0

4 20

08/0

7 20

08/1

0 20

09/0

1 20

09/0

4 20

09/0

7 20

09/1

0 20

10/0

1 20

10/0

4 20

10/0

7 20

10/1

0 20

11/0

1 20

11/0

4 20

11/0

7 20

11/1

0 20

12/0

1 20

12/0

4 20

12/0

7 20

12/1

0 20

13/0

1 20

13/0

4 20

13/0

7 20

13/1

0 20

14/0

1 20

14/0

4 20

14/0

7

Mill

ions

Number of Claims Served per Month Total Cost per Month

New claims subject to Formulary

Legacy claims subject to Formulary

Page 30: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 30

Number of claims by claim type by service month

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

0

5,000

10,000

15,000

20,000

25,000

30,000

35,000

40,000

45,000

50,000 20

11/0

1 20

11/0

2 20

11/0

3 20

11/0

4 20

11/0

5 20

11/0

6 20

11/0

7 20

11/0

8 20

11/0

9 20

11/1

0 20

11/1

1 20

11/1

2 20

12/0

1 20

12/0

2 20

12/0

3 20

12/0

4 20

12/0

5 20

12/0

6 20

12/0

7 20

12/0

8 20

12/0

9 20

12/1

0 20

12/1

1 20

12/1

2 20

13/0

1 20

13/0

2 20

13/0

3 20

13/0

4 20

13/0

5 20

13/0

6 20

13/0

7 20

13/0

8 20

13/0

9 20

13/1

0 20

13/1

1 20

13/1

2 20

14/0

1 20

14/0

2 20

14/0

3 20

14/0

4 20

14/0

5 20

14/0

6 20

14/0

7 20

14/0

8 20

14/0

9

Legacy claims

New claims

Total claims

Page 31: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 31

Total pharmacy costs by claim type by service month

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

$0

$2

$4

$6

$8

$10

$12

$14 20

11/0

1 20

11/0

2 20

11/0

3 20

11/0

4 20

11/0

5 20

11/0

6 20

11/0

7 20

11/0

8 20

11/0

9 20

11/1

0 20

11/1

1 20

11/1

2 20

12/0

1 20

12/0

2 20

12/0

3 20

12/0

4 20

12/0

5 20

12/0

6 20

12/0

7 20

12/0

8 20

12/0

9 20

12/1

0 20

12/1

1 20

12/1

2 20

13/0

1 20

13/0

2 20

13/0

3 20

13/0

4 20

13/0

5 20

13/0

6 20

13/0

7 20

13/0

8 20

13/0

9 20

13/1

0 20

13/1

1 20

13/1

2 20

14/0

1 20

14/0

2 20

14/0

3 20

14/0

4 20

14/0

5 20

14/0

6 20

14/0

7 20

14/0

8 20

14/0

9

Mill

ions

Legacy claims

New claims

Page 32: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 32

Average pharmacy cost per claim by claim type by service month

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

$0

$50

$100

$150

$200

$250

$300

$350

$400

$450

$500 20

11/0

1 20

11/0

2 20

11/0

3 20

11/0

4 20

11/0

5 20

11/0

6 20

11/0

7 20

11/0

8 20

11/0

9 20

11/1

0 20

11/1

1 20

11/1

2 20

12/0

1 20

12/0

2 20

12/0

3 20

12/0

4 20

12/0

5 20

12/0

6 20

12/0

7 20

12/0

8 20

12/0

9 20

12/1

0 20

12/1

1 20

12/1

2 20

13/0

1 20

13/0

2 20

13/0

3 20

13/0

4 20

13/0

5 20

13/0

6 20

13/0

7 20

13/0

8 20

13/0

9 20

13/1

0 20

13/1

1 20

13/1

2 20

14/0

1 20

14/0

2 20

14/0

3 20

14/0

4 20

14/0

5 20

14/0

6 20

14/0

7 20

14/0

8 20

14/0

9

Legacy claims

New claims

Page 33: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 33

Legacy claims: Costs of N-drugs and other drugs by service month

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

$0

$2

$4

$6

$8

$10

$12

$14

$16 20

11/0

1 20

11/0

2 20

11/0

3 20

11/0

4 20

11/0

5 20

11/0

6 20

11/0

7 20

11/0

8 20

11/0

9 20

11/1

0 20

11/1

1 20

11/1

2 20

12/0

1 20

12/0

2 20

12/0

3 20

12/0

4 20

12/0

5 20

12/0

6 20

12/0

7 20

12/0

8 20

12/0

9 20

12/1

0 20

12/1

1 20

12/1

2 20

13/0

1 20

13/0

2 20

13/0

3 20

13/0

4 20

13/0

5 20

13/0

6 20

13/0

7 20

13/0

8 20

13/0

9 20

13/1

0 20

13/1

1 20

13/1

2 20

14/0

1 20

14/0

2 20

14/0

3 20

14/0

4 20

14/0

5 20

14/0

6 20

14/0

7 20

14/0

8 20

14/0

9

Mill

ions

Other drugs

N-drugs

Page 34: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

February 2015 34

Share of N-drug cost in the total cost by claim type by service month

Source: Texas Department of Insurance, Workers’ Compensation Research and Evaluation Group, 2015.

0%

5%

10%

15%

20%

25%

30% 20

11/0

1 20

11/0

2 20

11/0

3 20

11/0

4 20

11/0

5 20

11/0

6 20

11/0

7 20

11/0

8 20

11/0

9 20

11/1

0 20

11/1

1 20

11/1

2 20

12/0

1 20

12/0

2 20

12/0

3 20

12/0

4 20

12/0

5 20

12/0

6 20

12/0

7 20

12/0

8 20

12/0

9 20

12/1

0 20

12/1

1 20

12/1

2 20

13/0

1 20

13/0

2 20

13/0

3 20

13/0

4 20

13/0

5 20

13/0

6 20

13/0

7 20

13/0

8 20

13/0

9 20

13/1

0 20

13/1

1 20

13/1

2 20

14/0

1 20

14/0

2 20

14/0

3 20

14/0

4 20

14/0

5 20

14/0

6 20

14/0

7 20

14/0

8 20

14/0

9

Legacy claims

New claims

Page 35: Impact of the Pharmacy Closed Formulary · 2020. 7. 15. · February 2015 3 . Summary of key findings: New claims . New claims with injuries that occurred on or after September 1,

REG’s main Web page at the Texas Department of Insurance: www.tdi.texas.gov/wc/regulation/roc

For more information, contact us at [email protected].

Per Chapter 405 of the Texas Labor Code, the Workers' Compensation Research and Evaluation Group at the Texas Department of Insurance is responsible for conducting professional studies and research on various system issues, including:

• the delivery of benefits; • litigation and controversy related to workers' compensation; • insurance rates and rate-making procedures; • rehabilitation and reemployment of injured employees; • the quality and cost of medical benefits; • employer participation in the workers' compensation system; • employment health and safety issues; and • other matters relevant to the cost, quality, and operational effectiveness of the workers' compensation system.